Optimierung der Chemotherapie durch Resistenz-Modulation

  • A. Schalhorn
  • M. Kühl
Conference paper

Zusammenfassung

Die Modulation der 5-Fluorouracil-Wirkung durch den Antimetaboliten Methotrexat (MTX), aber auch durch Nicht-Zytostatika wie z. B. durch Folinsäure oder Allopurinol ist von großem wissenschaftlichen Interesse und hat zumindest in der Folinsäure/5-Fluorouracil-Kombination auch eine klinische Bedeutung erlangt. Von Modulation der 5-FU-Wirkung spricht man, wenn eine oft selber nicht toxische Substanz in den Transport oder den Metabolismus von 5-FU so eingreift oder die Wirkung der 5-FU-Metaboliten so beeinflußt, daß es zu einer Potenzierung oder Abschwächung der 5-FU-Wirkung kommt. Da es sich bei der 5-FU-Modulation um Effekte handelt, die sich von der Biochemie, speziell der Pharmakodynamik des 5-FU herleiten, soll im folgenden erst der Metabolismus von 5-Fluorouracil besprochen werden. Daran anschließend werden die Prinzipien und ersten Ergebnisse einiger der möglichen 5-FU-Modulationen dargestellt.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Ahmann FR, Garewal H, Greenberg B (1986) Phase II trial of high-dose continuous infusion 5-fluorouracil with allopurinol modulation in colon cancer. Oncology 43: 83–85PubMedCrossRefGoogle Scholar
  2. 2.
    Ardalan B, Singh G, Silberman H (1989) A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonoacetyl)-1aspartic acid in patients with advanced pancreatic and colorectal cancers. J Clin Oncol 6: 1053–1058Google Scholar
  3. 3.
    Bertino JR, Mini E, Fernandes DJ (1983) Sequential methotrexate and 5-fluorouracil: mechanisms of synergy. Sem Oncol 10: 2–5Google Scholar
  4. 4.
    Bleyer WA (1989) New vistas for leucovorin in cancer chemotherapy. Cancer 63: 995–1007PubMedCrossRefGoogle Scholar
  5. 5.
    Canobbio L, Nobile MT, Galligioni E, Vidili G, Fassio T, Lo Re G, Rubagotti A, Rosso R (1987) Randomized trial of 5-fluorouracil alone or in combination with high-dose folinic acid in advanced colorectal cancer. ASCO Proc 6, No 318, p 97Google Scholar
  6. 6.
    Doroshow JH, Bertrand M, Multhauf P, Leong L, Goldberg G, Margolin K, Carr B, Akman S, Hill R (1987) Prospective randomized trial comparing 5-fluorouracil versus 5-fluorouracil and high-dose folinic acid for treatment of advanced colorectal cancer. ASCO Proc 6, No 374, p 96Google Scholar
  7. 7.
    Erlichman C, Fine S, Wong A, Elhakim T (1988) A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 6: 469–475PubMedGoogle Scholar
  8. 8.
    Evans RM, Laskin JD, Hakala MT (1981) Effect of excess folates and deoxyinosine on the activity and site of action of 5-fluorouracil. Cancer Res 41: 3288–3295PubMedGoogle Scholar
  9. 9.
    Fernandes DJ, Moroson BA, Bertino JR (1981) The role of methotrexate and dihydrofolate polyglutamates in the enhancement of fluorouracil action by methotrexate. Cancer Treat Rep 65: 29–35PubMedGoogle Scholar
  10. 10.
    Grem JL, Fischer PH (1985) Augmentation of 5-fluorouracil cytotoxicity in human colon cancer cells by dipyridamole. Cancer Res 45: 2967–2972PubMedGoogle Scholar
  11. 11.
    Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB (1987) Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 47: 2203–2206PubMedGoogle Scholar
  12. 12.
    Herrmann R, Knuth A, Kleeberg U, Middecke H (1988) Methotrexat/5-Fluorouracil (MTX/FU) sequentiell im Vergleich mit 5-Fluorouracil (FU)-Monotherapie beim metastasierenden kolorektalen Karzinom. Endauswertung einer randomisierten Multicenter-Studie. Klin Wochenschr 109: 254Google Scholar
  13. 13.
    Herrmann R, Spehn J, Beyer JH, v. Franqué U, Schmieder A, Holzmann K, Abel U (1984) Sequential methotrexate and 5-fluorouracil: Improved response rates in metastatic colorectal cancer. J Clin Oncol 2: 591–594PubMedGoogle Scholar
  14. 14.
    Howell SB, Wallace EW, Taetle R, Hussain F, Romine JS (1981) Modulation of 5fluorouracil toxicity by allopurinol in man. Cancer 48: 1281–1289PubMedCrossRefGoogle Scholar
  15. 15.
    Keyomarsi K, Moran RG (1986) Folinic acid augmentation of the effects of fluoropyrimidines on murine and human leukemic cells. Cancer Res 46: 5229–5235PubMedGoogle Scholar
  16. 16.
    Kobayashi S, Hoshino T (1983) Combined cytotoxic effect of low dose 5-fluorouracil and hydroxyurea on 9L cells in vitro. Cancer Res 43: 5309–5313PubMedGoogle Scholar
  17. 17.
    Köhne-Wömpner CH, Wilke H, Weiss J, Hiddemann W, Gropp C, Schmitz-Hübner U, Lohrmann HP, Bodenstein H, Urbanitz D, Hotz J, Preiß J, Knuth A, Schwark J, Bade J, Kohler B, Schmoll HJ (1989) Hochdosis Folinsäure (HDFA)/5-Fluorouracil (FU) versus FA/FU plus Dipyridamol ( D)-Vorläufige Ergebnisse einer randomisierten multizentrischen Phase-Il-Studie beim fortgeschrittenen kolorektalen Karzinom. Onkologie 12: 19–20CrossRefGoogle Scholar
  18. 18.
    Laufman LR, Krzeczowski KA, Roach R, Segal M (1987) Leucovorin plus 5fluorouracil: An effective treatment for metastatic colon cancer. J Clin Oncol 5: 1394–1400PubMedGoogle Scholar
  19. 19.
    Löffler TM, Korsten FW, Burghardt F, Aulbert E, Planker M, Lindemann M, Hausamen TU, Strohmeyer G (1989) Randomisierter Vergleich 5-FU vs. 5-FU/ Leukovorin beim fortgeschrittenen metastasierten kolorektalen Karzinom. Onkologie 12: 15CrossRefGoogle Scholar
  20. 20.
    Machover D, Goldschmidt E, Chollet P, Metzger G, Zittoun J, Marquet J, Vandenbulcke JM, Misset J, Schwarzenberg L, Fourtillon JB, Gaget H, Mathé G (1986) Treatment of advanced colorectal and gastric adenocarcinoma with 5fluorouracil and high-dose folinic acid. J Clin Oncol 4: 685–696PubMedGoogle Scholar
  21. 21.
    Moran RG (1989) Leucovorin enhancement of the effects of the fluoropyrimidines on thymidylate synthase. Cancer 63: 1008–1012CrossRefGoogle Scholar
  22. 22.
    Nobile MT, Vidili MG, Sobrero A, Sertoli MR, Canobbio L, Fassio T, Rubagotti A, Gallo L, Lo Re G, Galligioni E, Rosso R (1988) 5-Fluorouracil (FU) alone or a combined with high dose folinic acid (FA) in advanced colorectal cancer patients: randomized trial. ASCO Proc 7 No 371, p 97Google Scholar
  23. 23.
    Peters JP, Laurensse E, Leyva A, Pinedo HM (1987) Purine nucleosides as cell-specific modulators of 5-fluorouracil metabolism and cytotoxicity. Eur J Cancer Clin Oncol 23: 1869–1881PubMedCrossRefGoogle Scholar
  24. 24.
    Petrelli N, Douglass HO, Herrera L, Russell D, Stablein DM, Bruckner HW, Mayer RJ, Schinella R, Green MD, Muggia FM, Megibow A, Greenwald ES, Bukowski RM, Harris J, Levin B, Gaynor E, Loutfi A, Kaiser MH, Barkin JS, Benedetto P, Woolley PV, Nauta R, Weaver DW, Leichman LP for the Gastrointestinal Tumor Study Group (1989) The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase II trial. J Clin Oncol 7: 1419–1426PubMedGoogle Scholar
  25. 25.
    Petrelli N, Herrera L, Rustum Y, Burke P, Creaven P, Stulc J, Emrich LJ, Mittelman A (1987) A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 5: 1559–1565PubMedGoogle Scholar
  26. 26.
    Pinedo HM, Peters GFJ (1988) Fluorouracil: biochemistry and pharmacology. J Clin Oncol 6: 1653–1664PubMedGoogle Scholar
  27. 27.
    Poon MA, O’Connell MJ, Moertel CG, Wieand HS, Cullinan SA, Everson LK, Krook JE, Maillard JA, Laurie JA, Tschetter LK, Wiesenfeld M (1989) Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 7: 1407–1418PubMedGoogle Scholar
  28. 28.
    Schalhorn (1988) Clinical pharmacology of folinic acid and 5-Fluorouracil. In: Erlichman C (ed) Leucovorin: an expanding role in chemotherapy. Pharma Libri, Montreal, pp 33–50Google Scholar
  29. 29.
    Schalhorn A, Kühl M, Stupp-Poutot G, Nüssler V (1990) Pharmacokinetics of reduced folates after short-term infusion of d, 1-folinic acid. Cancer Chemother Pharmacol 25: 440–444PubMedCrossRefGoogle Scholar
  30. 30.
    Schalhorn A, Lerner J, Possinger K, Wilmanns W (1988) Folinic acid/5-fluorouracil in praetreated patients with far advanced colorectal carcinoma. J Cancer Res Clin Oncol 114: 25Google Scholar
  31. 31.
    Schalhorn A, Peyerl G, Denecke H (1988) Pharmacokinetics of 5-fluorouracil during isolated liver perfusion. Reg Cancer Treat 1: 21–27Google Scholar
  32. 32.
    Tsavaris N, Caragiauris P, Kosmidis P (1988) Reduction of oral toxicity of 5fluorouracil by allopurinol mouthwashes. Euro J Surg Oncol 14: 405–406Google Scholar
  33. 33.
    Valone FH, Friedman M, Wittlinger PS, Drakes T, Eisenberg PD, Malec M, Hannigan JF, Brown Jr BW (1989) Treatment of patients with advanced colorectal cancer with fluorouracil alone, high-dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil, and leucovorin: a randomized trial of the Northern California Oncology Group. J Clin Oncol 7: 1427–1436PubMedGoogle Scholar
  34. 34.
    Vokes EE, Panje WR, Weichselbaum RR, Schilsky RL, Moran WJ, Awan AM, Guarnieri CM (1988) Otolaryngol Head Neck Surg 98: 295–298PubMedGoogle Scholar
  35. 35.
    Wilmanns W, Schalhorn A (1989) Chemotherapie von Lebermetastasen kolorektaler Karzinome. In: Wannagat L (Hrsg) Onkologie — Tumoren des Verdauungstraktes. 2. Bad Mergentheimer Onkologisches Gespräch. Thieme, pp 161–176Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • A. Schalhorn
  • M. Kühl

There are no affiliations available

Personalised recommendations